Telmisartan

Telmisartan is indicated in the treatment of essential hypertension.The substance is quickly but to varying degrees absorbed from the gut. The average bioavailability is about 50% (42–100%). Food intake has no clinically relevant influence on the kinetics of telmisartan. Plasma protein binding is over 99.5%, mainly to albumin and alpha-1-acid glycoprotein.It has the longest half-life of any ARB (24 hours)and the largest volume of distribution among ARBs (500 liters).Less than 3% of telmisartan is inactivated by glucuronidation in the liver, and over 97% is eliminated in unchanged form via bile and faeces